

Q42021 Financial Results & Operating Highlights

March 10, 2022

ONCOCYTE™

Where Tomorrow LIVES

Forward Looking Statements

Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates," "may," and similar expressions) are forward-looking statements. These statements include, among others, those pertaining to the anticipated revenue impact, value creation roadmap, expected market differentiation, planned go-to market strategy, product development timeline, anticipated product launches and overall development and commercial strategy with respect to Oncocyte's "*Determa* Platform" and TheraSure™ Transplant-MONITOR, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management. Forward-looking statements involve risks and uncertainties, including, without limitation, the potential impact of COVID-19 on Oncocyte™ or its subsidiaries' financial and operational results, risks inherent in the development and/or commercialization of diagnostic tests or products, uncertainty in the results of clinical trials or regulatory approvals, the capacity of Oncocyte's third-party supplied blood sample analytic system to provide consistent and precise analytic results on a commercial scale, potential interruptions to supply chains, the need and ability to obtain future capital, maintenance of intellectual property rights in all applicable jurisdictions, and the need to obtain third party reimbursement for patients' use of any diagnostic tests Oncocyte or its subsidiaries commercialize, and risks inherent in strategic transactions such as the potential failure to realize anticipated benefits, legal, regulatory or political changes in the applicable jurisdictions, accounting and quality controls, potential greater than estimated allocations of resources to develop and commercialize technologies, or potential failure to maintain any laboratory accreditation or certification. Actual results may differ materially from the results anticipated in these forward-looking statements and accordingly such statements should be evaluated together with the many uncertainties that affect the business of Oncocyte, particularly those mentioned in the "Risk Factors" and other cautionary statements found in Oncocyte's Securities and Exchange Commission filings, which are available from the SEC's website. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Oncocyte undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

ONCOCYTE™

Our Mission


Oncocyte is a precision diagnostics company with a mission to improve patient outcomes by providing personalized insights that inform critical decisions throughout the patient care journey.



ONCOCYTE

The Emerging Patient Management Paradigm

Transforming a deadly disease to a chronic disorder



OCX's product offering delivers tests that make this a reality, allows us to tap into >$10B of Served Market value in US and Europe


Rx IO Tx Tissue Diagnostics

Blood Diagnostics CNI Mx Future Product

ONCOCYTE

Oncocyte's *Determa* Platform Strategy

Products Deliver Critical Information Throughout the Patient Journey Improving Outcomes and Reducing Costs




Differentiated Tests with **large TAMs (>$10B)** to Address Unanswered Questions Across **ALL** Stages of Cancer

ONCOCYTE™

Oncocyte 2022 Success Milestones

Market-focused initiatives to support clinical utility and oncologist adoption

- Registry execution
- Sales execution
- Add strategic sales territories
- KOL Presentations



- Full market launch of DetermaIO/Tx
- IO submission to CMS
- Continue IO clinical studies
- Close agreement with global platform Co.
- Initiate IVD IO development
- Tx submission to CMS

- Finalize LDT for Transplant
- Submit dossier for LCD approval
- Establish Clinical Trial/EAP
- Close platform partnership
- Initiate IVD development

- Tech transfer
- Establish CMS path
- Initiate EU/US studies
- Papers/abstracts at major meetings

EAP – Early Access Program / LDT = Lab Developed Test / LCD - Local Coverage Determination

ONCOCYTE™

DetermaRX Q4 – 2021 YE Highlights



- Completed Tech Transfer to Burning Rock
- Quarter over quarter US testing volumes grew 54% and revenues grew 104% vs Q3
- Samples volume grew 106% and Revenue grew 152% in Q42021 vs Q42020
- Ended 2021 with total of 429 onboarded physicians, a 202% increase YOY

ONCOCYTE

DetermaIO Q4 - 2021 YE Highlights

Should I give immunotherapy?



- Launched 7 early adopter sites via Early Access Program and established KOL Speaker Program
- First Randomized, Prospective Trial presented at ESMO
- Predictive data in TNBC presented at SABCS
- Presented data on over 1,000 patients to date across 4 major tumor types
- On-track for indication-specific CMS submission in 2022

ONCOCYTE™

DetermaTx Q4 - 2021 YE Highlights

Should I give targeted therapy?



- Completed In Silico design, received 1st custom panel in Q4
- Initiated Clinical Validation
- On track to complete clinical validation in late Q2
- 2H CMS Submission planned under existing LCD for Medicare coverage

ONCOCYTE

DetermaCNI Q4 - 2021 YE Highlights

- Blood-only test for monitoring
- Patented genome wide assessment offers advantages current MRD testing methods
- 5 publications to date – over 500 patients studied
  - 1200+ patients under study in EU across several solid tumor types
- RUO tech transfer to Nashville CLIA lab scheduled for Q2
- Ovarian Cancer paper published in December
  - Detected recurrence post surgery
- CMS Submission planned under existing LCD for Medicare coverage

Patient Monitoring


Is the therapy working?



DETERMA CNI™

For Research Use Only in EU
US 1H22

ONCOCYTE™



Transplant Update

Q4/2021 YE Earnings Call

03/10/22

ONCOCYTE™

Where Tomorrow LIVES

TheraSure Update

- Received dPCR patent for dd cfDNA Monitoring in Transplant and Oncology in Q4 ‘21
- Initiated LDT Tech Transfer from GmbH to Nashville in Q4 ’21
- On track for completion of LDT validation by end of Q1
- CMS Pre-meeting complete (early Dec 2021)
- Analytical validation and CMS Dossier for Liver on track for initial CMS submission followed by Kidney Q2’22
- Currently no competitive offerings in liver represents opportunity to be first to market and establish a foothold at centers prior to decentralized approach.

OCX 2021 Results



Where Tomorrow LIVES

ONCOCYTE™

Thank You

ONCOCYTE™



Investor Contact:
Mitch Levine
Chief Financial Officer
IR@oncocyte.com